1 hr 1 min
Episode 95 Biotech Hangout
-
- Life Sciences
On this week’s episode of Biotech Hangout, hosts Brad Loncar, Josh Schimmer, Grace Colon, Chris Garabedian, and Eric Schmidt discuss the latest biotech industry news including M&A, regulatory news, pricing strategies, and progress within women’s health and neurological disorders. The hosts cover data from Roche’s IL-6 program, Biohaven’s degrader program, followed by Crinetics’ Phase 3 data in acromegaly. On the M&A front, the hosts discuss AstraZeneca’s acquisition of Fusion Pharmaceuticals. The group also talks through Orchard Therapeutics’ breakthrough $4.25 million drug, and the impact of high drug prices on the industry as a whole. They also weigh in on the BioSecure bill that caused WuXi to leave BIO, and the broader impact of this decision on the biotech sector. The group also discussed a new executive order and initiatives that serve to address disparities in research for women’s health conditions. The hosts round out the show by discussing trends in early-stage investment, and the growing role of neurological conditions globally. *This episode aired on March 22, 2024.
On this week’s episode of Biotech Hangout, hosts Brad Loncar, Josh Schimmer, Grace Colon, Chris Garabedian, and Eric Schmidt discuss the latest biotech industry news including M&A, regulatory news, pricing strategies, and progress within women’s health and neurological disorders. The hosts cover data from Roche’s IL-6 program, Biohaven’s degrader program, followed by Crinetics’ Phase 3 data in acromegaly. On the M&A front, the hosts discuss AstraZeneca’s acquisition of Fusion Pharmaceuticals. The group also talks through Orchard Therapeutics’ breakthrough $4.25 million drug, and the impact of high drug prices on the industry as a whole. They also weigh in on the BioSecure bill that caused WuXi to leave BIO, and the broader impact of this decision on the biotech sector. The group also discussed a new executive order and initiatives that serve to address disparities in research for women’s health conditions. The hosts round out the show by discussing trends in early-stage investment, and the growing role of neurological conditions globally. *This episode aired on March 22, 2024.
1 hr 1 min